Monsoon Communications

Monsoon Communications is a premium investor and public relations firm, adding shareholder value to small and mid-cap companies.

[Monsoon Communications @MonsoonComms]

The next #TwilightInvestorBriefing is locked for 8 July, 3.45 PM AEST in Melbourne.

Join us & @FB_Rice for an evening with three #ASX biotechs at the forefront of promising new cancer therapies: $RAC, $ATX, $PTX.

Reserve your seat ⬇️
https://t.co/JmRT0YfiJ6

[Monsoon Communications @MonsoonComms]

$RAC: RC220 silences MYC — one of the most coveted targets in oncology — implicated in 70% of cancers, long considered undruggable

$ATX: 5 complete remissions never seen before in pancreatic cancer

$PTX: 100% clinical benefit rate in blood cancer

#ASX #TwilightInvestorBriefing

[Monsoon Communications @MonsoonComms]

The next #TwilightInvestorBriefing is locked for 8 July, 3.45 PM AEST in Melbourne.

Join us & @FB_Rice for an evening with three #ASX biotechs at the forefront of promising new cancer therapies: $RAC, $ATX, $PTX.

Reserve your seat ⬇️
https://t.co/JmRT0YfiJ6

[Monsoon Communications @MonsoonComms]

📢@AVITAMedical (ASX: $AVH) — Perth-invented burn technology, 5% penetration in a US$1.3B market, a US govt BARDA deal & RECELL GO now approved in ANZ. CEO Cary Vance in convo w/ Michael Woods on what's next.

Huge thanks @FB_Rice for hosting!

🔽Watch now
https://t.co/e7cOz5921L

[Monsoon Communications @MonsoonComms]

Cary Vance, CEO of @AvitaMedical will be in conversation with Michael Woods, CEO of Newburyport Partners and veteran healthcare investor, for a live Q&A on AVITA's portfolio and 2026 outlook.

Huge thanks to @FB_Rice for their generous support in making this evening possible.

[Monsoon Communications @MonsoonComms]

Next Thu 21 May at @FB_Rice Melbourne — @AVITAMedical (ASX: $AVH | NASDAQ: $RCEL): RECELL GO approved in Australia & NZ, 10-yr U.S. government BARDA deal signed, growing clinical evidence behind RECELL and Cohealyx. CEO Cary Vance on what's next.

RSVP ⬇️ https://t.co/p3MCRE8M0k

[Monsoon Communications @MonsoonComms]

📌 CLINUVEL Pharmaceuticals (ASX: $CUV) — 20 consecutive half-year profits, $233m cash, Nasdaq uplist in progress

📌 FOS Capital (ASX: $FOS) — founder-led consolidator, $115m quote book, government infrastructure tailwinds

#TwilightInvestorBriefing #ASX

[Monsoon Communications @MonsoonComms]

#TwilightInvestorBriefing is coming to Sydney, powered by @FB_Rice! 🌆

Featuring two dividend-paying ASX small caps (#ASX $CUV & $FOS) with proven business models and disciplined capital management.

Seats are limited. RSVP now ⬇️:
https://t.co/EDduPDF94G

[Monsoon Communications @MonsoonComms]

Highlights 💫

$NEU: DAYBUE STIX approved, Phase 3 enrolling in Phelan-McDermid, PRV potential ~US$200m
$ATH: 48% MSA disease slowdown, oral mechanism, Fast Track + Orphan status
$AGN: AI stroke efficacy signals, Phase 2b incoming, US$10.6bn market

#TwilightInvestorBriefing

[Monsoon Communications @MonsoonComms]

#TwilightInvestorBriefing is one week away!

Join us & @FB_Rice for an evening with three #ASX biotechs tackling neurological diseases with no approved treatments: $NEU, $ATH, $AGN.

Secure your seat ⬇️
https://t.co/Vfu40IKum2

[CLINUVEL @ClinuvelNews]

CLINUVEL was pleased to present at the #TwilightInvestorBriefing hosted by @MonsoonComms in Melbourne on 3 March 2026, focused on dividend paying companies. CFO Peter Vaughan and Head of Australian Operations & Investor Relations Malcolm Bull told CLINUVEL’s story to the investment community, highlighting the journey to profitability, now maintained for 9 1/2 years, and the payment of dividends for 8 consecutive years.

There was strong interest in the Company’s results for the half year to December 2025 and ongoing expansion to assist new patient populations, particularly vitiligo.

Thank you to Monsoon Communications and FB Rice for hosting the event and enabling us to highlight the determination and persistence needed in the biotech sector to achieve and maintain profitability and dividends.

#Dermatology #BioTech #Pharma #Vitiligo #EPP #SkinHealth #Science #ASX #Peptides $CUV.AX $CLVLY

[Monsoon Communications @MonsoonComms]

A huge thanks to @FB_Rice for hosting and sponsoring this event — your support of the ASX biotech investment community is greatly appreciated.

Navigating your next IP journey? Find out how they can help: https://t.co/CVcaAQCRSP

[Monsoon Communications @MonsoonComms]

#TwilightInvestorBriefing returns with three #ASX biotechs transforming neurological disease.

$NEU: royalty engine + Phase 3 catalyst
$ATH: first oral therapy for MSA, Phase 3 bound
$AGN: neuroprotection in stroke, AI-powered trial design

Register now: https://t.co/zBJdRlR2oM

[Monsoon Communications @MonsoonComms]

#TwilightInvestorBriefing is back.

Proudly sponsored by @FB_Rice, join us for three dividend-paying #ASX small caps with strong cash flow and profits: $CUV $VLS $FOS.

Tue 3 Mar 2026 | 4.30 PM AEDT at FB Rice, Melbourne.

🔗Register now: https://t.co/DOIEHHfNIO

[Biotron (ASX:BIT) @BiotronLimited]

Biotron CEO Dr Michelle Miller is joining @ausbiztv to discuss new HBV data. BIT-HBV001 shows strong in-vivo activity, outperforms the global standard of care, Tenofovir, in vitro. 🎥 Watch LIVE NOW: https://t.co/bTU6Xpu2ud

[Monsoon Communications @MonsoonComms]

Supported by @FB_Rice, #AUCARTShowcase brings @CarinaBiotech, @WeAreArovella (ASX: ALA) & @Chimeric (ASX: CHM) unveiling breakthrough CAR-T programs.

Chaired by Chris Kallos, CFA, senior life sciences analyst with 20+ yrs experience.

🔗 Register: https://t.co/OnhumAkwUc

[Biotron (ASX:BIT) @BiotronLimited]

Biotron (ASX:BIT) reports major progress on its HBV program.

BIT-HBV001 shows strong antiviral activity in two mouse models, broad inhibition across all key HBV markers incl. cccDNA, and synergy with Tenofovir. New patent filed.

Full update ⬇️
https://t.co/Xf3pQ4VuQV

[Biotron (ASX:BIT) @BiotronLimited]

Biotron Limited’s Managing Director, Dr Michelle Miller, and Sedarex Limited Director, Graeme-David Wald, shared an update on the Sedarex acquisition and introduce its next-generation general anaesthetic technology, SedRx™.

🎥 Watch now: https://t.co/hgUdYlcDwO

[Monsoon Communications @MonsoonComms]

⏳ Two weeks to #AUCARTShowcase!

Hear from three CAR-T leaders: @CarinaBiotech , @WeAreArovella & @Chimeric — advancing cancer innovation & investor opportunity in oncology.

🗓️ Register now: https://t.co/HCQUaCnqzC

[Biotron (ASX:BIT) @BiotronLimited]

Biotron outlines the next 12 months of milestones — from advancing its Hepatitis B program to SedRx’s regulatory and efficacy goals that open new blue-sky potential for investors.

🔗 Investor Inquiry: [email protected]
📺 Full Interview: https://t.co/2dx6e9F3gx

#Biotech #Sedarex

[Biotron (ASX:BIT) @BiotronLimited]

Biotron’s Sedarex acquisition signals a move beyond antivirals — introducing a near-term, revenue-ready asset while de-risking the portfolio for investors.

🔗 Investor Inquiry: [email protected]
📺 Full Interview: https://t.co/YyfRt5j7mT

#Biotech #Sedarex